Actively Recruiting

Early Phase 1
Age: 1Year - 21Years
All Genders
NCT05555550

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Led by Children's Hospital of Philadelphia · Updated on 2026-04-29

30

Participants Needed

1

Research Sites

57 weeks

Total Duration

On this page

Sponsors

C

Children's Hospital of Philadelphia

Lead Sponsor

B

Blue Earth Diagnostics

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.

CONDITIONS

Official Title

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Who Can Participate

Age: 1Year - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with Low Grade Glioma (WHO grade I-II) in the brainstem or supratentorial region, confirmed by biopsy unless classic appearance in NF1
  • Must have evaluable disease with at least 1x1 cm tumor visible on MRI
  • Scheduled to begin systemic therapy for Low Grade Glioma
  • Karnofsky score 65 50 if older than 16 years; Lansky score 65 50 if 16 years or younger; wheelchair-bound but ambulatory participants are included
  • Age between 1 and 21 years at registration
  • Being on a treatment regimen does not exclude participation
Not Eligible

You will not qualify if you...

  • Unable to tolerate imaging procedures as judged by physician
  • Pregnant participants
  • Weight less than 8 kilograms
  • Unable to avoid contact with pregnant women or infants for at least 12 hours after injection
  • History of abnormal kidney function or creatinine level 65 CTCAE v5.0 grade 2 at registration
  • Primary tumors located in the spinal cord

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Children s Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

M

Mariam Aboian, MD, PhD

CONTACT

N

Nazanin Maleki, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here